Allergy News and Research

RSS

The term allergy encompasses a wide range of conditions; it is not a disease in itself. In 1906 Clemens von Pirquet was the first to describe allergies as a changed or altered reaction of the immune system in response to exposure to foreign proteins. These days the term allergy – medically termed hypersensitivity, signifies an exaggerated reaction to foreign substances.

New data provide comprehensive review of emerging role of small airways in asthma management

Teva Respiratory, a division of Teva Pharmaceutical Industries Ltd., today announced the publication of four articles in a special supplement of the December issue of the Journal of Allergy and Clinical Immunology (JACI), providing a comprehensive scientific review of the emerging role of the small airways in the understanding and treatment of asthma.

8 Dec 2009

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Sickle cell disease, a condition characterized by deformed and dysfunctional red blood cells, is one of the most common genetic blood disorders affecting millions of people around the world, including more than 70,000 Americans (National Heart, Lung, and Blood Institute.

8 Dec 2009

H1N1 virus produces pulmonary damage similar to earlier flu pandemics

In fatal cases of 2009 H1N1 influenza, the virus can damage cells throughout the respiratory airway, much like the viruses that caused the 1918 and 1957 influenza pandemics, report researchers from the National Institutes of Health (NIH) and the New York City Office of Chief Medical Examiner.

8 Dec 2009

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Facet Biotech Corporation and Bristol-Myers Squibb Company announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented today at the American Society of Hematology (ASH) 2009 Annual Meeting in New Orleans.

8 Dec 2009

Prenatal exposure to microbes may help protect child from developing allergies later in life

A pregnant woman's exposure to microbes may protect her child from developing allergies later in life. Researchers in Marburg, Germany find that exposure to environmental bacteria triggers a mild inflammatory response in pregnant mice that renders their offspring resistant to allergies.

8 Dec 2009

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

La Jolla Pharmaceutical Company (“La Jolla”) today announced that it entered into a definitive merger agreement with Adamis Pharmaceuticals Corporation (“Adamis”) on December 4, 2009.

8 Dec 2009

H1N1 virus causes more life-threatening complications than seasonal flu

Infection with the H1N1 virus, or swine flu, causes more life-threatening complications than seasonal flu in children with sickle cell disease, according to research from Johns Hopkins Children's Center.

8 Dec 2009

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

Adamis Pharmaceuticals Corporation (OTCBB: ADMP), announced today that it has entered into a definitive merger agreement providing for the acquisition of La Jolla Pharmaceutical Company by Adamis.

7 Dec 2009

Smoking cessation offers measurable benefits for asthmatic patients

Asthmatic smokers may be able to reverse some of the damage to their lungs that exacerbates asthmatic symptoms just by putting down their cigarettes, according to research out of the University of Groningen in the Netherlands.

7 Dec 2009

GSK places a batch of AS03 adjuvanted H1N1 vaccine on hold

Following reports from Canada's Public Health Agency that six patients had suffered allergic reactions after receiving the shot, GlaxoSmithKline plc has voluntarily placed a hold on a single batch of the AS03 adjuvanted H1N1 vaccine Arepanrix in Canada as a precautionary measure.

4 Dec 2009

PRP shows strong potential for accelerated healing of dental implant procedures

An exciting treatment gaining acceptance in orthopedics and sports medicine, called platelet-rich plasma therapy (PRP), is showing strong potential for accelerated healing of dental implant procedures, according to a prominent dental researcher and editor of the Journal of Oral Implantology.

4 Dec 2009

Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist

Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM461, the Company's second oral selective antagonist of the DP2 (also known as CRTH2) receptor.

3 Dec 2009

Cielo MedSolutions, DrFirst partner to provide a comprehensive e-prescribing solution

Cielo MedSolutions today announced a new partnership with DrFirst to provide comprehensive e-prescribing functionality to practices using the company's Cielo Clinic clinical quality management system. The fully integrated e-prescribing solution will enable customers to improve prescribing safety and medical practice efficiency.

3 Dec 2009

NIDA funds proposed 'seek and treat' strategy in the fight against HIV/AIDS

Dr. Julio Montaner - Director, British Columbia Centre for Excellence in HIV/AIDS (BC-CfE), and President, International AIDS Society - congratulated Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH), for taking a leadership role in the evaluation of the "Seek and Treat" strategy originally developed at the BC-CfE.

3 Dec 2009

NHLBI awards new federal grant to improve the quality of stored transfusion blood

A new, $2.8 million, four-year federal grant will support researchers at the University of Pittsburgh School of Medicine and their collaborators at Wake Forest University as they study why the quality of stored transfusion blood degrades over time and how to address the problem.

3 Dec 2009

Kalbitor drug approved by FDA

The U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).

2 Dec 2009

FDA grants approval for Dyax' KALBITOR for treating HAE patients

Dyax Corp. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

2 Dec 2009

Op-eds on World AIDS Day: Research, funding, hunger, Uganda

The "National Institutes of Health - perhaps our best hope for funding a cure for AIDS - has been underfunded since 2003," Kate Krauss, director of the AIDS Policy Project, writes in a Philadelphia Inquirer opinion piece.

1 Dec 2009

Color-coded IV lines with labels to help differentiate multiple lines and avoid errors

Hospitals continue to develop new and improved communications strategies so doctors, nurses and technicians can provide the best patient care. In some hospital wards speed and accuracy are essential - especially the critical care unit / ICU.

1 Dec 2009

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

Ardea Biosciences, Inc. announced positive results from the first dosing group of an ongoing drug-drug interaction and pharmacodynamic study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen). This

1 Dec 2009

Allergy News and Research

Further Reading

New data provide comprehensive review of emerging role of small airways in asthma management

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

H1N1 virus produces pulmonary damage similar to earlier flu pandemics

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Prenatal exposure to microbes may help protect child from developing allergies later in life

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

H1N1 virus causes more life-threatening complications than seasonal flu

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

Smoking cessation offers measurable benefits for asthmatic patients

GSK places a batch of AS03 adjuvanted H1N1 vaccine on hold

PRP shows strong potential for accelerated healing of dental implant procedures

Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist

Cielo MedSolutions, DrFirst partner to provide a comprehensive e-prescribing solution

NIDA funds proposed 'seek and treat' strategy in the fight against HIV/AIDS

NHLBI awards new federal grant to improve the quality of stored transfusion blood

Kalbitor drug approved by FDA

FDA grants approval for Dyax' KALBITOR for treating HAE patients

Op-eds on World AIDS Day: Research, funding, hunger, Uganda

Color-coded IV lines with labels to help differentiate multiple lines and avoid errors

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News